identified trust in medical doctors, coping, family role functioning, chronicity of disease, drugs, family support, functions related to pregnancy, need for medications and side effects of medications to be important concepts for SLE [3, 4] . Similar to LupusQoL, we did identify importance of relationships with family, friends, intimate partner and effects on sex. As the tool has undergone further validation studies, using clinimetric and psychometric approaches, these items were not be ranked highly and were dropped. Receiving support from partner/family or friends was considered more important and were retained. Lupu-sPRO's face validity has been tested since the initial publication, in two focus groups independently, during the development of the lupus impact tracker [5] . Other conceptual coverage errors noted in Table two pertain to conceptual coverage of "weakness", "sleep", "relationships", "work disability" and "economic impact" by SF36. Hence, the generalization that SF-36, LupusQoL and SLEQOL demonstrated greatest level of conceptual coverage as compared to other tools seems erroneous.
Other psychometric properties: LupusPRO has excellent construct validity against EQ5D, SF-36, depression and body image tools in the original English version, as well as in various languages and regions [2, [6] [7] [8] [9] [10] . It is responsive to change against self-reported change in health status [2] , physician global assessment [2, 11, 12] , BILAG [2] , LFA defined flare [2] , SLEDAI [11, 12] and SELENA Flare Index [11, 12] . SLEQOL, LupusPRO, LupusQoL [13, 14] and SF-36 [15] have been noted to have high floor/ceiling effects (>15%). SF-36 has been reported to have high floor and ceiling effects in several diseases [16] [17] [18] , and is used widely in research and clinical trials, including SLE. Infact, floor and ceiling effects of SF-36 were reported in the SLEQOL development study among SLE patients [15] . The authors should note that LupusQoL and LupusPRO have been cross culturally validated in several languages and regions, and continue to show fair psychometric properties. In addition, LupusPRO is the only tool thus far to demonstrate measurement equivalence of the tool across languages and regions [19] . The statement that only L-QoL and LupusQoL had sufficient evidence of validity for SLE population is incorrect. Perhaps the authors wished to indicate in the table is the floor effects, and not its construct validity.
Item formatting: Though the authors differ in opinion, we feel that wording of LupusQoL items 10, 11 and 15 of LupusQoL may be confusing to the patient about the concept/s being measured. For example, item 10, interference of sleep by pain from lupus is being sought. A patient may have difficulty ascribing causality of the pain to lupus, and then to their sleep. In addition, a lupus patient with sleep interference, but from lupus related fatigue, depression or anxiety may endorse the item.
A tool with low ceiling and floor effects is preferable; however, not every concept measured has a true hierarchy of difficulty or ability. Furthermore, the domain may be measuring the range of the concept that is appropriate for the selected population. We need further studies to explore and understand this issue. Greater collaboration would lead us to further patient reported outcomes research and clinical trials in SLE to improve patients overall outcomes and quality of life.
Sincerely Meenakshi Jolly, MD Winston Sequeira, MD Joel A Block, MD
